tetano
Editor, Senior Moderator
WHO Guidelines for Pharmacological Management of Pandemic Influenza A(H1N1) 2009 and Other Influenza Viruses.
Source
Geneva: World Health Organization; 2010 Feb.
WHO Guidelines Approved by the Guidelines Review Committee.
Excerpt
The purpose of this document is to provide a basis for advice to clinicians on the use of the currently available antivirals for patients presenting with illness due to influenza virus infection as well the potential use of the medicines for chemoprophylaxis. The document addresses specifically the two neuraminidase inhibitors oseltamivir and zanamivir, and the two M2 inhibitors amantadine and rimantadine. It includes recommendations on the use of some other potential pharmacological treatments. While the focus of the document is on management of patients with pandemic influenza (H1N1) 2009 virus infection, the document includes guidance on the use of the antivirals for other seasonal influenza virus strains, and for infections due to novel influenza A virus strains. WHO recommends that country and local public health authorities issue local guidance for clinicians from time to time that places these recommendations in the context of epidemiological and antiviral susceptibility data on the locally circulating influenza strains.
Copyright ? 2010, World Health Organization.
Sections
Part 1. Recommendations
Summary
1. Introduction
2. Case description
3. Risk groups
4. Epidemiology
5. General Considerations
6. Recommendations
7. Other interventions for management of patients with influenza
8. Product supply
9. Priorities for update
10. Priorities for research
Annex 1 Risk factors for severe disease
Annex 2 List of participants
Annex 3 Declarations of Interests
Annex 4 Table of standard dosages
Part 2. Review of evidence
Summary of Evidence for Benefits and Harms
Annex 4 Methods used to prepare guidelines
Annex 5 Summaries of findings tables
Annex 6 Summary of observational data
Annex 7 Independent evaluation of oseltamivir dosing in children
Annex 8 Review of extemporaneous preparations of oseltamivir
References
PMID:
23741777
[PubMed]
Books & DocumentsFree full text
http://www.ncbi.nlm.nih.gov/pubmed/23741777
Source
Geneva: World Health Organization; 2010 Feb.
WHO Guidelines Approved by the Guidelines Review Committee.
Excerpt
The purpose of this document is to provide a basis for advice to clinicians on the use of the currently available antivirals for patients presenting with illness due to influenza virus infection as well the potential use of the medicines for chemoprophylaxis. The document addresses specifically the two neuraminidase inhibitors oseltamivir and zanamivir, and the two M2 inhibitors amantadine and rimantadine. It includes recommendations on the use of some other potential pharmacological treatments. While the focus of the document is on management of patients with pandemic influenza (H1N1) 2009 virus infection, the document includes guidance on the use of the antivirals for other seasonal influenza virus strains, and for infections due to novel influenza A virus strains. WHO recommends that country and local public health authorities issue local guidance for clinicians from time to time that places these recommendations in the context of epidemiological and antiviral susceptibility data on the locally circulating influenza strains.
Copyright ? 2010, World Health Organization.
Sections
Part 1. Recommendations
Summary
1. Introduction
2. Case description
3. Risk groups
4. Epidemiology
5. General Considerations
6. Recommendations
7. Other interventions for management of patients with influenza
8. Product supply
9. Priorities for update
10. Priorities for research
Annex 1 Risk factors for severe disease
Annex 2 List of participants
Annex 3 Declarations of Interests
Annex 4 Table of standard dosages
Part 2. Review of evidence
Summary of Evidence for Benefits and Harms
Annex 4 Methods used to prepare guidelines
Annex 5 Summaries of findings tables
Annex 6 Summary of observational data
Annex 7 Independent evaluation of oseltamivir dosing in children
Annex 8 Review of extemporaneous preparations of oseltamivir
References
PMID:
23741777
[PubMed]
Books & DocumentsFree full text
http://www.ncbi.nlm.nih.gov/pubmed/23741777